Clinical Trials

80 enrolled

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT06561074 2026-03-16

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

22 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06712121 2026-02-02

Venetoclax and Decitabine in R/R T-ALL

28 enrolled

Lymphoma

NCT06803693 2025-12-08

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

152 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06686108 2025-05-07

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

59 enrolled

Leukemia, Recurrence, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06941688 2025-04-24

Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma

Phase 2 Terminated

17 enrolled

Lymphoma, T-Cell, Peripheral

NCT06393985 2024-11-19

Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

30 enrolled

Burkitt Lymphoma

NCT05348213 2024-10-23

R-ICE+X

76 enrolled

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06441097 2024-06-04

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

152 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05816746 2023-05-09

Decitabine and Anti-PD-1 in R/R DLBCL

20 enrolled

Extranodal Extension, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05137886 2021-12-17

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

47 enrolled

Hodgkin Disease, Recurrence

NCT04025593 2020-11-19

Biomarker Guided Treatment in DLBCL

128 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04514081 2020-08-18

The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

200 enrolled

Hodgkin Disease

NCT04233294 2020-08-14

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

100 enrolled

Hodgkin Disease

NCT04279379 2020-05-07

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

20 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT03250962 2019-04-01

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

280 enrolled

Hodgkin Disease, Recurrence

NCT00882206 2017-12-28

Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia

Phase 2 Terminated

15 enrolled 8 charts